眼科 ›› 2015, Vol. 24 ›› Issue (2): 79-84.doi: 10. 13281/j. cnki. issn.1004-4469. 2015. 02. 003

• 论著 • 上一篇    下一篇

中国人可疑遗传性视神经萎缩患者OPA1基因突变分析及临床特征

谢玥 陈洁琼 许可 刘丽娟 张晓慧 蒋凤 董冰 李杨   

  1. 100005  首都医科大学附属北京同仁医院 北京同仁眼科中心 北京市眼科研究所 眼科学与视觉科学北京市重点实验室
  • 收稿日期:2015-02-12 出版日期:2015-03-25 发布日期:2015-04-06
  • 通讯作者: 李杨 , Email: yanglibio@aliyun.com
  • 基金资助:

    北京市卫生系统高层次卫生技术人才项目( 2013-2-021);国家自然科学基金( 81170878)

Characteristics of OPA1 genotype in Chinese patients with suspected hereditary optic atrophy

XIE Yue, CHEN Jie-qiong, XU Ke, LIU Li-juan, ZHANG Xiao-hui, JIANG Feng, DONG Bing, LI Yang   

  1. Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing 100005, China
  • Received:2015-02-12 Online:2015-03-25 Published:2015-04-06
  • Contact: LI Yang, Email: yanglibio@aliyun.com

摘要: 目的 分析中国人常染色体显性遗传性视神经萎缩(ADOA)OPA1基因突变特点及ADOA患者临床特征。设计 回顾性病例系列。研究对象 北京同仁医院可疑 ADOA患者291例,其中 55例家族史明确,236例为散发患者。方法 用PCR扩增DNA测序方法检测291例患者OPA1基因28个编码外显子,记录ADOA患者的临床特征。主要指标  OPA1基因突变,家族史,发病年龄,视力,眼底表现。结果 在291例患者中60例(20.6%)检测到51种OPA1基因致病突变,其中37种为本实验室新发现或首先报道的突变。基因突变中43%(22/51)为错义突变,19%(10/51)为无义突变,14%(7/51)为剪接位点突变,24%(12/51)为缺失或插入。OPA1基因突变主要分布于外显子27和9,频次分别为8和6次;其次为外显子8,26,28,频次均为5次。在 60例ADOA患者中,6例(10%)携带相同缺失突变c.2708_2711delTTAG。ADOA患者中男女比例为1.4:1,发病年龄(7.97±7.31)岁(范围3~33岁),女性患者发病年龄小于男性。平均 logMAR视力(0.84± 0.42)。60例患者均双眼同时发病,眼底表现对称,45例(75%)表现为双眼视盘颞侧色淡,13例(22%)表现为双眼全视盘色淡。结论 本研究结果扩大了 OPA1基因突变谱,外显子8,9,26-28是ADOA患者OPA1基因突变的热突变区域,对可疑ADOA患者应进行OPA1基因测序。(眼科,2015, 24: 79 -84)

关键词: 常染色体显性遗传性视神经萎缩, OPA1基因突变

Abstract: Objective To report the results of mutation analysis of the OPA1 gene in a cohort of patients with suspected hereditary optic atrophy and describe clinical features of autosomal dominant optic atrophy (ADOA) patients. Design Retrospective case series. Participants Two hundred and ninety-one suspected ADOA probands who have been excluded from 16 primary mitochondrial DNA mutations associated with Leber hereditary optic neuropathy (LHON) in our prior screening. Among them 55 had a family history of hereditary optic neuropathy, and 236 were sporadic cases. All patients were unrelated. Methods The coding region (exon 1-28), including intron-exon boundary of the OPA1 gene, were screened in participants and some family members by using PCR-based sequencing methods. The clinical features of ADOA patients were recorded. Main Outcome Measures Mutations of OPA1 gene, family history, age of onset, visual acuity, and fundus photography. Results Fifty-one OPA1 pathogenic mutations were found in 60 patients (60/291, 20.6%). Of the 51 intragenic mutations, 37 were detected for the first time in this study or in our precious studies. The mutations contained 43% (22/51) of missense mutations, 19% (10/51) of nonsense mutations, 14% (7/51) of splice site mutations, and 24% (12/51) of deletions or insertions. The majority of OPA1 intragenic mutations were located in exon 27 and 9, for 8 and 6 times, respectively. Followed by exon 8, 26 and 28, where mutations had been identified 5 times. One reported mutation c.2708_2711delTTAG in exon 27 was identified in 6 unrelated probands. The male-to-female ratio of the 60 positive probands was almost 1.4:1. The mean onset age of visual deficit was 7.97±7.31 years (ranging from 3-33 years) and the mean logMAR visual acuity for the probands carrying OPA1 mutations was 0.84±0.42. Sixty ADOA patients presented with bilateral, symmetric visual failure and optic nerve degeneration. In this study, the appearance of the optic nerve head was divided into two categories, with a prominent temporal wedge pallor in 45 of 60 patients (75%) and total disc pallor observed in 13 of 60 patients (22%). Conclusion Our findings expand the spectrum of OPA1 mutation and the exon 8, 9 and 26 to 28 were the hot regions of OPA1 gene mutations. It is important to perform an OPA1 gene mutation analysis for patients with suspected autosomal dominant optic atrophy. (Ophthalmol CHN, 2015, 24: 79-84)

Key words: autosomal dominant optic atrophy(ADOA), OPA1 mutations